The effect of intravesical gemcitabine on prevention of recurrence in non-muscle-invasive bladder cancer

Comparing the intravesical effect of gemcitabine with distilled water after trans urethral resection of tumor on prevention of recurrence in non-muscle-invasive bladder cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220207053961N1

Enrollment

134

Registered

2022-04-03

Start date

2022-05-20

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder tumor. Malignant neoplasm of bladder

Interventions

Intervention 1: Intervention group: At the end of the surgery, 2000 mg of gemcitabine will be dissolved in 100 ccs of normal saline and injected into the duct through a catheter and the catheter will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with non-muscle-invasive bladder cancer Patients candidate of trans urethral resection of tumor (TURT) Tumor size less than or equal to 3 cm Low grade tumor on cystoscopy Diagnosed tumors in first time

Exclusion criteria

Exclusion criteria: Frequent recurrence Tumor size above 3 cm

Design outcomes

Primary

Measure	Time frame
Tumor size. Timepoint: Three and six months after surgery. Method of measurement: In millimeters on sonography.;Tumor recurrence. Timepoint: Three and six months after surgery. Method of measurement: Having a recurrence based on sonography.	—

Secondary

Measure	Time frame
Tumor site. Timepoint: Three and six months after surgery. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Sadri

Oroumia University of Medical Sciences

sadri.m@umsu.ac.ir+98 44 3345 7286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026